Dacomitinib

A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa

Medicine & Technology Jun 06, 2017

In the last day of ASCO 2017 annual meeting on Tuesday, researchers presented the data of Dacomitinib that delayed the growth of the lung cancer longer than Gefitinib, trademarked as Iressa in newly diagnosed patients.

Dacomitinib

A Clinical Study Finds Pfizer's Dacomitinib Delays The Growth of Lung Cancer Cells Better Than AstraZeneca's Iressa

Most Popular

H5N1 Bird Flu Has Spread to Humans With 'Extraordinarily High' Mortality Rate, WHO Warns

Roman Lead Coffin Found To Hold Previously Unknown Human Child Remains in Fascinating Discovery

Pluto's Heart: Massive Ancient Collision May Explain How Dwarf Planet's Unique Heart-Shaped Feature Formed, Scientists Discover

Why Do People Struggle to Remember Mundane Things Like Passwords, Locking the Front Door?

Indestructible Tardigrades Survive Radiation by Ramping Up Production of DNA Repair Genes

Recommended Stories

Cheap Satellites Like SpaceX’s Starlink Could Disrupt Earth’s Magnetosphere and Expose Us to Deadly Cosmic Rays, Ex-NASA Physicist Warns

Tachyon Domination: Researchers Suggest the Universe May Be Full of Invisible Particles That Break Causality and Travel Faster Than Light

Sat-Nav in Space: Best Route Between Two Worlds Calculated Using 'Knot Theory' [Study]

When's the Best Time to Watch the Lyrids Meteor Shower That Will Peak This Weekend?